All News

The addition of immunotherapy to radiotherapy increased the overall survival of patients with cancer who developed brain metastases, according to new research.

Opioids are a common tool in treating cancer-related pain, but they are also at the center of a nationwide epidemic. One that researchers have found cancer patients are not as linked to as previously thought.

The Food and Drug Administration approved the expanded use of the biomarker test CINtec PLUS Cytology that looks at HPV related biomarkers that could lead to cervical cancer. This is the first triage test approved in this space.

As a caregiver, you rarely have 10 seconds to think or reflect on anything, but with my husband gone now, I find myself looking back more than ever. There are so many things we did right, and so many things I’ll probably always feel unsure of.

Recent immunotherapy approvals for patients with metastatic melanoma has widened the treatment landscape, but new research shows that patients associated with positive sociodemographic factors are more likely to receive immunotherapy.

Neuropathy causes tingling or numbness, especially in the hands and feet. It affects about one to two percent of Americans and is caused by damage to a single or multiple nerves. There are different types, but peripheral neuropathy is the most common in those with cancer.

Younger and female patients with a variety of cancer types tend to have strong immune systems that naturally fight an array of cancer cells. The tumor cells the immune system doesn’t destroy are the most evasive, both to the immune system and medications that boost its activity, and this makes checkpoint inhibitor immunotherapy less effective in this population.

Please, look for advice and resources that do not further complicate or adversely affect your own efforts to cope, but rather offers a path for you to do the best for your kids but still focus on all the aspects of you and your whole family living with cancer.

CURE® compiled a roundup of five recent reports patients with skin cancer may have missed.

The data demonstrated that the addition of Ninlaro to Revlimid and dexamethasone led to a 13.5-month increase in median progression-free survival, compared with placebo. However, the data failed to meet the threshold for statistical significance.

On social media, CURE® recently asked its readers to share how they overcome the fear that comes with cancer. Here, we share some of their responses.

Cancer survivors are like bumblebees in that they continue to go on and fly despite the countless obstacles they face.

Fear of having cancer is not unusual, but there are a few actions you can take to help calm those fears

“With education and awareness to defeat the stigma, resources for those diagnosed, and innovative research toward cures, we can end colorectal cancer in our lifetime,” Michael Sapienza, CEO of Colorectal Cancer Alliance, said in a statement.

We arrived in a remote region of Long Island just in time to sit back on the deck overlooking the bay and catch a magical, breathtaking sunset. Five years of struggling through cancer, we’d damn well earned this moment.

A proposed preventive surgery that would take out fallopian tubes before menopause but save ovary removal until afterwards was favored by most premenopausal previvors of ovarian cancer in a study.

The study results also showed that older age was significantly associated with lower cancer genetics knowledge, which, according to a post-doctoral research fellow at Dana-Farber Cancer Institute, is important because older adults may serve as a resource for family members who seek information about their family's health history.

Cancer survivors sometimes wonder about their purpose on earth as time passes and so many others pass away before us with cancer. We need to be gentle with ourselves and not stress to much.

From the passing of famed Game of Thrones actress Dame Dianna Rigg after a lung cancer diagnosis to the recording of a confrontational call between a three-time cancer survivor and her senator’s staffer, here’s what’s happening in the cancer headlines this week.

Forty percent of patients with triple-refractory multiple myeloma achieved a response after receiving 60 millicurie (a unit of radioactivity) or greater of CLR 131.

Compared to physician’s choice of chemotherapy, the MEK inhibitor Mektovi failed to improve progression-free survival in patients with low-grade serous ovarian carcinomas. However, the study authors note Mektovi demonstrated promising results that support continued use of the treatment.

When compared with the standard of care triplet regimen of Velcade, Revlimid and dexamethasone, the combination of Kyprolis, Revlimid and dexamethasone did not demonstrate superior treatment results in patients with newly diagnosed multiple myeloma.

I received a phone call that would alter the course of my life in ways that I couldn’t possibly have imagined. On the other end was my 27-year-old daughter and I sat dazed and confused as she tearfully said, “Mom … it’s cancer.”

Adding Venclexta to Vidaza chemotherapy improved survival and boosted the complete remission rate in previously untreated patients with AML who had coexisting health conditions and/or were age 75 or older, results from a phase 3 clinical trial showed.

Supportive and palliative care are critical for people living with cancer to better manage treatment-related side effects.

The FDA based its decision on data from a phase 3 trial which showed that adding plinabulin to Neulasta significantly improved the rate of severe chemotherapy-induced neutropenia.

There have been several drug approvals and updates from the Food and Drug Administration (FDA) in the cancer space over the last several weeks.

The Food and Drug Administration’s warning comes weeks after Genentech, the manufacturer of Tecentriq, issued a press release noting that the IMpassion131 trial failed to meet its primary endpoint of improving progression-free survival in patients with triple-negative breast cancer.

“Our hope is that this will enable us to reduce or eliminate late effects of treatment that persist into the survivorship years,” Dr. Peter Cole, of Rutgers Cancer Institute of New Jersey, said in a press release.

An author and two-time cancer survivor offers fellow writers some advice on what they’ll need to know if they’re considering writing a book about surviving cancer.